Study S000337

The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00630825
Acronym: EGO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 262
Start: 2008-04
Primary completion: 2009-01
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:LY2189265; DRUG:Placebo
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBCJ

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus [Baseline, 16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.